SML3898
P144 diammonium
≥95% (HPLC)
Synonym(s):
Disitertide diammonium, P144 diammonium, Peptide 144 diammonium, TSLDASIIWAMMQN diammonium, Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn diammonium
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C68H109N17O22S2
Molecular Weight:
1580.82
NACRES:
NA.77
UNSPSC Code:
12352200
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Human type 3 TGF-β receptor sequence-derived TGF-beta1 (TGF-β1) inhibitor that blocks TGF-β1-mediated responses in vitro and in vivo.
P144 (Disitertide) is a 14-aa peptide TGF-beta1 (TGF-β1) inhibitor whose sequence corresponds to aa731-744 of human type 3 TGF-β receptor (UniProt Q03167). P144 blocks TGF-β1 from binding the type 3 TGF-β receptor and inhibits TGF-β1-mediated responses in vitro (80% MV1Lu growth inhibition by 200 μg/mL P144 in the presence of 200 pg/mL human TGF-β1) and in vivo (57% inhibition of hepatic stellate cells (HSCs) activation in a rat model of CCl4 inhalation-induced cirrhosis/hepatic fibrosis; 70 μg P144/rat via q.o.d. i.p.).
P144 (Disitertide) is a 14-aa peptide TGF-beta1 (TGF-β1) inhibitor whose sequence corresponds to aa731-744 of human type 3 TGF-β receptor (UniProt Q03167). P144 blocks TGF-β1 from binding the type 3 TGF-β receptor and inhibits TGF-β1-mediated responses in vitro (80% MV1Lu growth inhibition by 200 μg/mL P144 in the presence of 200 pg/mL human TGF-β1) and in vivo (57% inhibition of hepatic stellate cells (HSCs) activation in a rat model of CCl4 inhalation-induced cirrhosis/hepatic fibrosis; 70 μg P144/rat via q.o.d. i.p.).
Disclaimer
Hygroscopic
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy
International Journal of Cancer. Journal International Du Cancer, 125(11), 2614-2623 (2009)
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis
The Journal of Investigative Dermatology, 125(3), 450-455 (2005)
A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury
Cytokine, 22(1-2), 12-20 (2003)
Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library
Cytokine, 39(2), 106-115 (2007)
P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model
Current Oncology (Toronto, Ont.), 29(4), 2650-2661 (2022)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service